Literature DB >> 33641255

Analyzing and predicting the LNM rate and prognosis of patients with intraductal papillary mucinous neoplasm of the pancreas.

Chao-Tao Tang1, Bi-Xia Liu1, Youxiang Chen1, Chunyan Zeng1.   

Abstract

BACKGROUND: Current the surveillance and management are controversial for patients with IPMN. We aimed to develop an alternative nomogram to individualize IPMN prognosis and LNM.
METHODS: Based on the data from SEER database of patients diagnosed with IPMN between 2004 and 2015, a nomogram predicting the survival and LNM of IPMN based on univariate and multivariate and Lasso regression analysis was performed, internally and externally validated, and measured by C-index, and decision curve analysis (DCA), and compared to the 7th TNM stage.
RESULTS: A total of 941 patients were included. Age, T stage examined nodes, tumor size, and pathology grade were identified as an independent factor for predicting LNM. The nomogram we established to predict LNM had a high predicting value with a C-index value of 0.735 and an AUC value of 0.753. Interestingly, including T1 stage, we found an inverse correlation was between age and LNM. In addition, nomogram for predicting CSS also performed better than TNM stage both in the internal validation group (1-year AUC:0.753 vs. 0.693, 3-year AUC: 0.801 vs. 0.731, 5-year AUC: 0.803 vs. 0.733) and external validation group (1-year AUC: 0.761 vs. 0.701, 3-year AUC: 0.772 vs. 0.713, 5-year AUC:0.811 vs. 0.735). DCA analysis showed the nomogram showed a greater benefit across the period of follow-up compared to 7th TNM stage.
CONCLUSION: A nomogram based on multivariate and Lasso regression analysis showed great clinical usability compared with current criteria. Also, for LNM of IPMN, younger age patients with IPMN should be attached more importance.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LNM; intraductal papillary mucinous neoplasm (IPMN); nomogram; survival; validation study

Mesh:

Year:  2021        PMID: 33641255      PMCID: PMC7957210          DOI: 10.1002/cam4.3632

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  31 in total

1.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

2.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.

Authors:  Seiko Hirono; Yasuhiro Shimizu; Takao Ohtsuka; Toshifumi Kin; Kazuo Hara; Atsushi Kanno; Shinsuke Koshita; Keiji Hanada; Masayuki Kitano; Hiroyuki Inoue; Takao Itoi; Toshiharu Ueki; Toshio Shimokawa; Susumu Hijioka; Akio Yanagisawa; Masafumi Nakamura; Kazuichi Okazaki; Hiroki Yamaue
Journal:  J Gastroenterol       Date:  2019-08-28       Impact factor: 7.527

3.  Inverse Association of Age with Risk of Lymph Node Metastasis in Superficial Colorectal Cancer: A Large Population-Based Study.

Authors:  Qing-Wei Zhang; Long-Ci Sun; Chao-Tao Tang; Qian Liang; Yang-Yang Zhou; Hui-Min Chen; Yun-Jie Gao; Zhi-Zheng Ge
Journal:  Oncologist       Date:  2020-01-10

4.  Validation of Indications for Surgery of European Evidence-Based Guidelines for Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms.

Authors:  I-Shiow Jan; Ming-Chu Chang; Ching-Yao Yang; Yu-Wen Tien; Yung-Ming Jeng; Chih-Horng Wu; Bang-Bin Chen; Yu-Ting Chang
Journal:  J Gastrointest Surg       Date:  2020-11       Impact factor: 3.452

5.  The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Kenjiro Kimura; Ryosuke Amano; Sadaaki Ymazoe; Go Ohira; Kohei Nishio; Kosei Hirakawa; Masaichi Ohira
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

6.  What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year.

Authors:  Rym El Khoury; Christopher Kabir; Vijay K Maker; Mihaela Banulescu; Margaret Wasserman; Ajay V Maker
Journal:  Ann Surg Oncol       Date:  2018-03-20       Impact factor: 5.344

7.  Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.

Authors:  Taylor S Riall; Victoria M Stager; William H Nealon; Courtney M Townsend; Yong-fang Kuo; James S Goodwin; Jean L Freeman
Journal:  J Am Coll Surg       Date:  2007-03-23       Impact factor: 6.113

8.  European evidence-based guidelines on pancreatic cystic neoplasms.

Authors: 
Journal:  Gut       Date:  2018-03-24       Impact factor: 23.059

9.  A New Metastatic Lymph Node Classification-based Survival Predicting Model in Patients With Small Bowel Adenocarcinoma: A Derivation and Validation Study.

Authors:  Shan Wu; Jin-Nan Chen; Qing-Wei Zhang; Chao-Tao Tang; Xin-Tian Zhang; Ming-Yu Tang; Xiao-Bo Li; Zhi-Zheng Ge
Journal:  EBioMedicine       Date:  2018-06-13       Impact factor: 8.143

Review 10.  Observation or resection of pancreatic intraductal papillary mucinous neoplasm: An ongoing tug of war.

Authors:  Jan Rune Aunan; Nigel B Jamieson; Kjetil Søreide
Journal:  World J Gastrointest Oncol       Date:  2019-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.